Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder

Last updated: March 27, 2025
Sponsor: VA Office of Research and Development
Overall Status: Active - Recruiting

Phase

N/A

Condition

Post-traumatic Stress Disorders

Treatment

tcVNS

sham

Clinical Study ID

NCT05517304
MHBP-004-21F
I01 CX002331
I01CX002331
  • Ages 18-75
  • All Genders

Study Summary

This study effects the effects of transcutaneous cervical vagal nerve stimulation (tcVNS) or a sham control on brain, physiology, and PTSD symptoms in Veterans with posttraumatic stress disorder (PTSD). Veterans undergo brain imaging and physiological measures in conjunction with traumatic scripts before and after three months of twice daily treatment with tcVNS or sham stimulation at home.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Veterans between the ages of 18 and 75 will be included with a diagnosis of PTSDbased on DSM-5 criteria

Exclusion

Exclusion Criteria:

Subjects will be excluded with:

  • a history of mild traumatic brain injury (mTBI) based on VA Criteria

  • moderate or greater TBI

  • positive pregnancy test

  • meningitis or other neurological disorder

  • alcohol or substance abuse use disorder based on DSM-5 criteria within the past 12months

  • current or lifetime history of schizophrenia, schizoaffective disorder, bipolar Idisorder, anorexia nervosa or bulimia, based on DSM-5

  • active suicidal ideation with a plan

  • a history of serious medical or neurological illness, such as cardiovascular,gastrointestinal, hepatic, renal, neurologic or other systemic illness that wouldpreclude participation based on clinical judgment of the PI

  • active opiate or benzodiazepine treatment

  • history of structural abnormality on brain MRI or CT if one has been performed inthe past

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: tcVNS
Phase:
Study Start date:
October 01, 2022
Estimated Completion Date:
November 17, 2026

Study Description

Description: This study assesses brain function measured with High Resolution Positron Emission Tomography (HR-PET) during exposure to stressful traumatic scripts paired with tcVNS or sham stimulation, with secondary measures of blood inflammatory biomarkers, and sympathetic function. Participants then undergo three months of twice daily home treatment with repeat measures.

Drug/Device Handling: [O-15] radiolabeled water has a half-life of 110 seconds and is made on site at the Emory Center for Systems Imaging (CSI). Dr. Bremner holds the Investigational New Drug (IND) approval for use of radiolabeled water at Emory University. The investigators have performed hundreds of studies in human subjects at Emory and there have been no adverse events or untoward effects to date.

tcVNS with the GammaCore device is approved by the Emory IRB for a recently completed study in PTSD and others in progress for Opioid Use Disorder and was shown to be well tolerated and there have been no adverse events or untoward effects with the device. The FDA granted Breakthrough Device Designation for PTSD for the gammaCore tcVNS device based on the investigators' studies. Devices are blinded by ElectroCore and the devices and information are kept by the Data Manager under double lock and key. Device records are kept by the Data Manager and stored on Redcap or secured research drives. Devices are given to the study team along with a device schedule under direct supervision from the investigator.

Connect with a study center

  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia 30033-4004
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.